Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (361)	12/28/1997 5:53:00 PM
From: flickerful	Respond to of 756

<<Strange how these technical advancements occur at such moment>> about as strange as taxol being mentioned friday as a potential alzheimer treatment modality...there seems in place always some scheme, some interrelated development. only now...maybe IVX will benefit, rather than the rest of the free world at their expense. do you find there seems a quid pro quo in this biotech madness, some big chits that trade behind the trades? jackson, i agree it would minimize overhead: i only wish we knew more of the market, although novartis DID provde a handle. of one thing we may be assured, it is vast: how vast we may soon know in light of this. the plot thickens...( i imagine also this would provide insulation from potential liability in the context of "monitoring", a real nightmare in practice, i bet) later, randy

To: 5,17,37,5,101,... who wrote (361)	12/28/1997 6:25:00 PM
From: flickerful	Respond to of 756

related item... F D A ÿ P r o f i l e ÿÿÿ September 1997ÿÿÿ ÿFDA Backs Decreased WBC Testing For Patients on Clozapine The FDA's Psychopharmacologic Drugs Advisory Committee has recommended that white blood cell counts for schizophrenics on clozapine (Clozaril) be performed on a biweekly basis after the patient's first six months on the drug. The FDA reconsidered the frequency of testing because a number of patients wrote the agency seeking a reduction in the frequency of monitoring. The patients claimed that a weekly blood draw was a hurdle to the initiation of therapy. Novartis Pharmaceuticals, the producer of Clozaril, had cautioned against a reduction in testing frequency, and noted that it would lead to more cases of agranulocytosis. Roughly 150,000 patients have taken clozapine since its launch in 1990. Click "Back" on your browser to return to your search results. Copyright c 1997 AACC - All Rights Reserved. aacc.org

To: 5,17,37,5,101,... who wrote (361)	12/29/1997 2:57:00 AM
From: flickerful	Respond to of 756

i was snooping around the net, and looked in at the fda site... specifically at the drug patent and exclsitvity list...i wanted to also see how those "new" applications were pouring in. fda.gov (which still lists the expiration as aug 4, 2000) the patent code= U-198 TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA new indication= I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA